NeuBase Therapeutics, Inc.NBSE
Market cap
$1.41M
P/E ratio
| Sep 30, 2011 | Sep 30, 2012 | Sep 30, 2013 | Sep 30, 2014 | Sep 30, 2015 | Sep 30, 2016 | Sep 30, 2017 | Sep 30, 2018 | Sep 30, 2019 | Sep 30, 2020 | Sep 30, 2021 | Sep 30, 2022 | |
| General and administrative | 997,816 | 1 | 1 | 555,735 | 8 | 8 | 5 | 4 | 9 | 10 | 12 | 12 |
| Research and development | 800,520 | 2 | 5 | 4 | 9 | 16 | 17 | 4 | 4 | 7 | 11 | 21 |
| Research and development, Vera acquisition | - | - | - | - | - | - | - | - | - | - | 3 | - |
| TOTAL OPERATING EXPENSES | 4 | 7 | 12 | 9 | - | - | - | - | 26 | 17 | 27 | 33 |
| LOSS FROM OPERATIONS | -1,243,401 | -3,286,408 | -4,620,916 | -9,122,924 | -17,805,280 | -24,596,053 | -23,780,073 | -13,903,955 | -26,336,407 | -17,069,306 | -26,565,447 | -33,318,339 |
| Interest expense | 49,723 | 51,540 | 56,229 | 5,576 | 5,977 | - | - | - | 128,951 | 7,686 | 32,330 | 24,047 |
| Interest income | - | - | - | - | - | - | - | - | - | - | 12,550 | 148,556 |
| Change in fair value of warrant liabilities | - | - | - | - | - | - | - | - | 492,889 | 453,808 | -950,151 | - |
| Equity in losses on equity method investment | - | - | - | -10,643 | -103,143 | - | - | - | - | -262,861 | -224,534 | -415,747 |
| Other (expense) income, net | 63,413 | 63,525 | 154,284 | 8,479 | 42,966 | - | -1,349 | 592,584 | - | -315,214 | 1 | -166,873 |
| Total other (expense) income, net | -2,279,711 | 2 | -1,031,572 | -7,740 | 3 | -1,170,145 | -30,923 | 667,055 | - | - | - | -458,111 |
| NET LOSS | -5,101,519 | -1,454,884 | -5,652,488 | -9,130,664 | -15,197,865 | -25,766,198 | -23,810,996 | -13,236,900 | -26,958,247 | -17,384,520 | -25,409,301 | -33,776,450 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | - | -0.93 | -1.04 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | - | -0.93 | -1.04 |